首页> 外文期刊>Bioorganic and medicinal chemistry >Antisense peptide nucleic acid-peptide conjugates for functional analyses of genes in Pseudomonas aeruginosa
【24h】

Antisense peptide nucleic acid-peptide conjugates for functional analyses of genes in Pseudomonas aeruginosa

机译:用于铜绿假单胞菌基因功能分析的反义肽核酸-肽结合物

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Pseudomonas aeruginosa is one of the most common and clinically important pathogens because of its resistance to a wide variety of antibiotics. A number of treatments of P. aeruginosa have been developed, but there is still no definitive one. Antisense drugs have a great potential to treat multidrug-resistant P. aeruginosa because this technology, in principle, can inhibit the expression of any essential genes. Nucleic Acid Ther. 2012, 22, 323 reported that peptide nucleic acid (PNA) antisenses conjugated to the carrier peptide (RXR) 4 and targeted to ftsZ and acpP (essential genes) had antibacterial activity in P. aeruginosa. However, growth inhibition was also found with peptide-PNA antisense conjugates of mismatched sequences (negative controls), and hence there remains a possibility for considerable enhancement of basal level activity due to the general toxicity. To assess the true potential of peptide-PNA conjugates, we measured sequence-dependent knockdown of the (RXR)(4)-PNA conjugates by using a scrambled sequence as a negative control. In addition, we evaluated (RXR)(4)-PNA antisenses against three other essential genes (lepB, lptD and mraY) and a non-essential gene (PA1303), and confirmed that multiple sequences targeting only the essential genes showed antimicrobial activity in P. aeruginosa PAO1 cells. We also conducted a rescue experiment and confirmed that the antimicrobial activity of anti-mraY antisenses was an on-target effect, not due to general toxicity. These findings indicate that the (RXR)(4)-PNA antisense should be a useful tool for target validation of a specific gene and could be a therapeutic platform capable of targeting a variety of genes in P. aeruginosa. (C) 2015 Elsevier Ltd. All rights reserved.
机译:铜绿假单胞菌对多种抗生素具有抗性,因此是最常见和临床上重要的病原体之一。已经开发了许多铜绿假单胞菌的治疗方法,但是仍然没有确定的治疗方法。反义药物在治疗多药耐药的铜绿假单胞菌方面具有巨大潜力,因为该技术原则上可以抑制任何必需基因的表达。核酸疗法。 2012,22,323报告说,缀合到载体肽(RXR)4上并靶向ftsZ和acpP(必需基因)的肽核酸(PNA)对铜绿假单胞菌具有抗菌活性。但是,还发现了序列不匹配的肽-PNA反义缀合物的生长抑制作用(阴性对照),因此由于普遍的毒性,仍有可能显着提高基础水平的活性。为了评估肽-PNA偶联物的真正潜力,我们通过使用加扰序列作为阴性对照,测量了(RXR)(4)-PNA偶联物的序列依赖性敲低。此外,我们评估了(RXR)(4)-PNA对其他三个必需基因(lepB,lptD和mraY)和一个非必需基因(PA1303)的反义,并确认仅针对必需基因的多个序列在大肠杆菌中显示出抗菌活性。铜绿假单胞菌PAO1细胞。我们还进行了抢救实验,并确认抗mraY反义物的抗菌活性是一种靶标效应,而不是由于一般毒性所致。这些发现表明,(RXR)(4)-PNA反义应该是用于特定基因靶标验证的有用工具,并且可能是能够靶向铜绿假单胞菌中多种基因的治疗平台。 (C)2015 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号